WILMINGTON, Mass., July 20, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 45 QS-B220 desktop explosives trace detectors across international airports in the Czech Republic.
The selection of Implant Sciences' QS-B220 by international airports in the Czech Republic adds to the growing list of airports in Europe that have chosen Implant Sciences' superior performance over competing systems after head-to-head airport trials. The company believes that its QS-B220's value proposition, low false alarm rate, and high degree of efficiency drove these purchase decisions.
"We believe that we are witnessing a major tipping point in the ETD industry, with Implant Sciences being the catalyst. We have brought together a team replete with industry knowledge, technical expertise, and business know-how, and we have leveraged solid partnerships with key distributors. We believe we have developed the best ETD system by making a product that is simple and economical to use. Our systems' capabilities and performance have been proven as we beat our competitors in the lab and in operational trials," stated Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing.
"Our 'culture of service' - our unwavering commitment to customer satisfaction, as well as placing importance on teamwork and internally treating each other as important stakeholders - has set us apart in the industry," Dr. Jones added. "All of these factors have come together in such a way that has elevated Implant Sciences and enabled us to be recognized as an emerging market leader."
"I am truly proud and humbled to be a part of such an amazing team, producing such an important, cutting-edge product, and helping to provide critical security to the traveling public all around the world. Implant Sciences takes its mission very seriously: to be the market leaders and industry experts in trace detection technologies, but more importantly, to help people get home safely to their families at the end of the day," added Dr. Bill McGann, CEO of Implant Sciences.
About the QS-B220 Desktop Explosives and Drugs Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the GSN Homeland Security Award for "Best Explosives Detection Solution" two years in a row (2013 and 2014). All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Implant Sciences Corporation
978-752-1700 x 116
SOURCE Implant Sciences Corporation